(IBTX) Announces Share Repurchase Program

MCKINNEY, Texas, Jan. 23, 2015  — Independent Bank Group, Inc. (Nasdaq:IBTX), the holding company for Independent Bank, today announced that the Board of Directors has authorized the repurchase of up to $30 million of its common stock. The Company plans to repurchase its shares in open market transactions from time to time or through privately negotiated transactions, at the Company’s discretion.

Commenting on the announcement David R. Brooks, Chairman and CEO, said, “As we continue to execute our growth strategy, both organically and through strategic acquisitions, we believe the adoption of a stock repurchase program provides us with an additional tool with which to enhance stockholder value. We plan to implement the program at such time and price as repurchases are considered beneficial to the Company and its stockholders.” Brooks continued, “The Board’s approval of a stock repurchase program reflects continued confidence in our ability to execute the Company’s key strategies.”

The repurchase program is authorized to continue through December 31, 2015. The timing and amount of any share repurchases will depend on a variety of factors, including the trading price of the Company’s common stock, securities laws restrictions including but not limited to compliance with blackout periods, regulatory requirements, potential alternative uses for capital, and market and economic conditions. The Company intends to fund any repurchases through its consolidated earnings and borrowings under its revolving credit facility. Repurchased shares will be cancelled and returned to unissued status. The repurchase program does not obligate the Company to acquire any particular amount of shares and the repurchase program may be modified, suspended or discontinued at any time, at the Company’s discretion.

About Independent Bank Group

Independent Bank Group, through its wholly owned subsidiary, Independent Bank, provides a wide range of relationship-driven commercial banking products and services tailored to meet the needs of businesses, professionals and individuals. Independent Bank Group operates 39 banking offices in three market regions located in the Dallas/Fort Worth, Austin and Houston, Texas areas.

CONTACT: Analysts/Investors:

         Torry Berntsen
         President and Chief Operating Officer
         (972) 562-9004
         tberntsen@ibtx.com

         Michelle Hickox
         Executive Vice President and Chief Financial Officer
         (972) 562-9004
         mhickox@ibtx.com

         Media:

         Eileen Ponce
         Marketing Director
         (469) 301-2706
         eponce@ibtx.com

(LGCY) Cash Distributions, 2015 Capital Budget, Year-End Conference Call

MIDLAND, Texas, Jan. 23, 2015  — Legacy Reserves LP (“Legacy”) (Nasdaq:LGCY) today announced that the Board of Directors of its general partner has approved a cash distribution attributable to the fourth quarter of 2014 of $0.61 per unit, payable on February 13, 2015, to unitholders of record at the close of business on February 2, 2015.

Legacy’s general partner also declared a cash distribution for both its 8% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Units and its 8% Series B Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Units of $0.166667 per unit payable on February 17, 2015 to preferred unitholders of record on February 2, 2015.

The Board also approved a 2015 capital budget of $30 million as compared to approximately $130 million in 2014. Cary D. Brown, Chairman, President and Chief Executive Officer of Legacy’s general partner, commented: “The dramatic drop in oil and gas prices has directly impacted our asset-level project returns. While we have commodity hedges in place to insulate our near-term cash flow at the partnership level, it simply does not make economic sense to pursue new drilling projects in this market environment as they do not generate a sufficient return for the company. We are encouraged that our third-party service providers have already begun to reduce prices, but we will need to see further reductions prior to reinstating our prior capital spending levels.

“We also realize that if the current price environment is a longer term cycle, we will not be able to continue to distribute to our common unitholders at these levels. We have always taken a long-term view on distributions and we do not believe the current commodity outlook is sustainable. We have a strong balance sheet and near-term hedges to mitigate against this dramatic downturn. With our retail investors in mind, we believe it is best to maintain our distribution level this quarter to give us more time to assess our long-term distribution capabilities in a more stabilized market. We appreciate our retail unitholders and believe this strategy gives them time to plan around any possible reduction in future distributions. We are hopeful that with good acquisitions and some price improvement, a distribution reduction will not be necessary. However, we remain committed to only distributing what the assets allow over a longer-term period.

“We are thankful for our hard-working employees, long-lived and low-decline asset base, protective commodity hedges, and incredibly strong balance sheet that will help protect us this year. We are hopeful that these difficult industry conditions can present the kinds of unique and large-scale opportunities that we have benefited from in our past. We look forward to sharing our thoughts around our 2015 outlook at our upcoming year-end earnings call.”

Legacy will provide the details of its fourth quarter and 2014 operating and financial performance with its earnings report which is scheduled to be released on Wednesday, February 25, 2015, following the close of NASDAQ trading.

Earnings Conference Call

A teleconference and webcast will be held on Thursday, February 26, 2015, beginning at 9:00 a.m. Central Time. Those wishing to participate in the conference call should dial 877-266-0479. A replay of the call will be available through Thursday, March 5, 2015, by dialing 855-859-2056 or 404-537-3406 and entering replay code 70464452. Those wishing to listen to the live or archived webcast via the Internet should go to the Investor Relations tab of our website at www.LegacyLP.com.

About Legacy Reserves LP

Legacy Reserves LP is a master limited partnership headquartered in Midland, Texas, focused on the acquisition and development of oil and natural gas properties primarily located in the Permian Basin, Mid-Continent and Rocky Mountain regions of the United States. Additional information is available at www.LegacyLP.com.

Cautionary Statement Relevant to Forward-Looking Information

This press release contains forward-looking statements relating to our operations that are based on management’s current expectations, estimates and projections about its operations. Words such as “anticipates,” “expects,” “intends,” “plans,” “targets,” “projects,” “believes,” “seeks,” “schedules,” “estimated,” and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements are realized oil and natural gas prices; production volumes, lease operating expenses, general and administrative costs and finding and development costs; future operating results and the factors set forth under the heading “Risk Factors” in our annual and quarterly reports filed with the Securities and Exchange Commission. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. The reader should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Unless legally required, Legacy undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Withholding Information

This release is intended to be a qualified notice under Treasury Regulation Section 1.1446-4(b). Brokers and nominees should treat one hundred percent (100.0%) of Legacy’s distributions to foreign investors as being attributable to income that is effectively connected with a United States trade or business. Accordingly, Legacy’s distributions to foreign investors are subject to federal income tax withholding at the highest applicable rate.

CONTACT: Legacy Reserves LP
         Dan Westcott
         Executive Vice President and Chief Financial Officer
         432-689-5200

(ABTL) Pioneer of the Automotive Internet Celebrates 20 Incredible Years

IRVINE, Calif., Jan. 23, 2015 — Autobytel (Nasdaq:ABTL), pioneer of the automotive Internet and the company dedicated to connecting automotive consumers with dealers, today announced it is celebrating its 20^th Anniversary this year, and is officially kicking off that celebration at the NADA Convention & Expo in San Francisco today.

The company says it has a host of exciting events planned at the show, including workshops entitled Text and Engage with Today’s Changing Customer, conducted by Scott Pechstein, Autobytel’s VP of National Sales; its exciting Dealer of the Year Award presentation; and its exclusive 20^th Anniversary Reception for dealers and automotive industry elite, among others.

“This is an extraordinary year as we celebrate 20 years of excellence and innovation, and over 50 million leads delivered to our industry partners since our launch,” said Jeff Coats, President and CEO of Autobytel Inc. “Before any other automotive website existed, Autobytel revolutionized an entire industry, and we continue to innovate today. We thank the tens of millions of consumers and the thousands of dealers and industry partners who have relied on Autobytel to improve the car buying and selling process these past two decades. We look forward to the next 20 years.”

In addition to its rich history in the automotive industry, the company says it has plenty to celebrate, highlighting incredible milestones it has achieved along the way:

• From its inception in 1995 to December 2014, the company has delivered over 50 million new and used car leads to its industry partners.¹
• In 1997, it garnered its one millionth customer and that same year, it became the first Internet Company to advertise on the Super Bowl. It advertised on the Super Bowl again in 1998.
• In 1999, it was heralded as the 7^th Most Recognized eCommerce Brand in the World, and it held its Initial Public Offering.²
• In 2000, it was named a permanent member of the Smithsonian National Museum of American History.
• In 2001, Autobytel recognized its 10 millionth customer.
• In 2004, for the sixth year in a row, Deloitte & Touche named Autobytel one of the 50 fastest growing technology companies in Orange County, California, and Autobytel executives rang the NASDAQ opening bell.
• In 2005, Autobytel celebrated its 10^th Anniversary.
• In 2008, Autobytel board member Jeff Coats took over the role as President and CEO and has since guided the company to 14 consecutive quarters of profitability.
• In 2010, the company acquired Cyber Ventures and Autotropolis, which enhanced the company’s internal lead generation efforts and expanded its search engine marketing footprint.
• In 2013, Autobytel acquired Advanced Mobile (now Autobytel Mobile) enabling the company to offer the auto industry a full suite of mobile products and services, including TextShield^™, an innovative lead management system for text, and a completely redesigned, cutting edge app for dealers.
• Also in 2013, Autobytel teamed with SaleMove, allowing dealers and manufacturers to enhance the online shopping experience by interacting with consumers in real-time via Virtual Showroom Technology.
• In 2014, Autobytel announced its acquisition of AutoUSA, a move that increased Autobytel’s national dealer network to 5,200, while boosting its business with auto manufacturers.
• Also in 2014, Autobytel delivered 6.4 million new and used car leads to its industry partners, and in the first six months of 2014 alone, it represented nearly 600,000 new and used car sales in the U.S.
• Today, the Autobytel YouTube channel has garnered close to 50 million views since its launch just three years ago.

The company invites you to watch its 20^th Anniversary Commemorative Video (http://youtu.be/MpxG8ND7DnM), as it celebrates its past accomplishments and its innovations for the road ahead.

Visit http://dealer.autobytel.com and http://mobile.autobytel.com to learn about the company’s leading industry products. Visit http://autobytel.com/ for leading automotive information; watch exclusive new car videos, test drives and car reviews at Autobytel’s YouTube channel; or join the conversation at the Autobytel Facebook Fan Page.

1) Autobytel audited lead totals from 1997 – 2014; estimated lead totals from 1995 – 1997

2) Results of Opinion Research Corporation consumer survey

About Autobytel Inc.

Autobytel Inc. provides high quality consumer leads and associated marketing services to automotive dealers and manufacturers throughout the United States and offers consumers robust and original online automotive content to help them make informed car-buying decisions. The company pioneered the automotive internet in 1995 with its flagship website http://www.autobytel.com/ and has since helped tens of millions of automotive consumers research vehicles; connected thousands of dealers nationwide with motivated car buyers; and helped every major automaker market its brand online.

Investors and other interested parties can receive Autobytel news releases and invitations to special events by accessing the online registration form at investor.autobytel.com/alerts.cfm.

CONTACT: Autobytel Inc. Media Relations
         Splash Media
         Jennifer Lange
         949-916-4820
         jlange@getsplashmedia.com
         or
         Autobytel Inc. Investor Relations
         Curtis DeWalt
         Chief Financial Officer
         949-437-4694
         curtisd@autobytel.com
         or
         Cody Slach or Sean Mansouri
         Liolios Group, Inc.
         949-574-3860
         abtl@liolios.com

(GPRO) NHL, NHLPA Partner With GoPro To Deliver Hockey Fans Unique Perspectives Of The Game

HD Video Content Captured with GoPro Cameras Will Be Used in NHL Game Broadcasts and on NHLPA, NHL and GoPro Online Channels GoPro Cameras to Deliver Real-Time Content to Live Broadcasts of 2015 Honda NHL All-Star Skills Competition and 2015 Honda NHL All-Star Game

NEW YORK and TORONTO, Jan. 23, 2015 — The National Hockey League (NHL) and the National Hockey League Players’ Association (NHLPA) today announced a North American partnership with GoPro, the maker of the world’s most versatile camera and enabler of some of today’s most immersive and engaging content. The agreement is GoPro’s first with a major professional sports league. As part of this unprecedented partnership, the NHL will use GoPro’s innovative equipment and expertise to deliver hockey fans never-before-seen perspectives of the game and the talents of the top players in high-definition video content during national and regional game broadcasts and across the digital and social media platforms of the NHLPA, NHL and GoPro.

To mark another first, GoPro’s Professional Broadcast Solution, developed in a partnership with Vislink, will deliver live HD points of view and will debut during the 2015 NHL^® All-Star Weekend, which will be held Jan. 23-25 in Columbus, Ohio. GoPro cameras worn by players will deliver real-time HD content and multiple angles and views to bring viewers even closer to the action on the ice for the 2015 Honda NHL All-Star Skills Competition™ on Saturday, Jan. 24 (7 p.m. ET on NBCSN, CBC, TVA Sports). Additional GoPro points of view are anticipated for the live broadcast of the 2015 Honda NHL® All-Star Game on Sunday, Jan. 25 (5 p.m. ET on NBCSN, CBC, TVA Sports).

“GoPro is the perfect partner for us in our ongoing commitment to bring hockey fans closer to the game,” said Bob Chesterman, NHL Senior Vice President of Programming and Production. “As the preeminent leader in adaptable cameras, only GoPro has the technology to help us and our media partners showcase the beauty and intensity of hockey in new and deeper ways. Our partnership with GoPro will be a big win for both new and lifelong hockey fans.”

“This partnership marks a significant first step for GoPro into team sports, made possible because of NHL and NHLPA’s progressive thinking,” said Todd Ballard, Senior Director of Lifestyle Marketing at GoPro. “Together we will push the boundaries of video content production in hockey and provide fans of the sport with unique, immersive perspectives of the game that they’ve never seen before, from players and officials to in-goal and rink side.”

Video content captured with GoPro cameras throughout the season, including the 2015 NHL All-Star Weekend, will offer fans an immersive experience. Game broadcasts will use the content to provide deeper layers of storytelling and to showcase the skating, stickhandling, goal scoring and netminding skills of some of the biggest names in the NHL. On-ice footage of the best players in the world is among the point-of-view GoPro content fans can expect this season.

“The use of GoPro cameras will give fans a new perspective of the extraordinary speed and skill of today’s NHL players,” said Mathieu Schneider, NHLPA Special Assistant to the Executive Director. “We are excited to have GoPro working with us and the NHL to show the great athleticism of our players.”

As part of the agreement, GoPro is an Official Partner of the NHLPA and the NHL and will receive prominent brand exposure across the NHL’s broadcast, digital and social media platforms – including NHL Network™, NHL.com, Facebook, Instagram, Twitter and Vine. NHL video content will be featured on some of GoPro’s dedicated media channels, including the GoPro YouTube channel.

ABOUT THE NHL
The National Hockey League (NHL®), founded in 1917, consists of 30 Member Clubs, each reflecting the League’s international makeup with players from more than 20 countries represented on team rosters, vying for the most cherished and historic trophy in professional sports – the Stanley Cup®. Every year the NHL entertains more than 250 million fans in-arena and through its partners on national television and radio; more than 10 million fans on its social platforms; and more than 300 million fans online at NHL.com. In Canada, the 2014-15 season marks the beginning of a landmark 12-year broadcast and multimedia agreement with Rogers Communications, which includes national rights to NHL games on all platforms in all languages. In the U.S., the NHL is in the fourth season of its 10-year agreement with NBC and NBCSN, the 10^th consecutive season both networks have served as national television partners. The NHL is committed to giving back to the community with programs including: Hockey is for Everyone™, which supports nonprofit youth hockey organizations across North America; Hockey Fights Cancer™, raising money for local and national cancer organizations; NHL Green™, which is committed to pursuing sustainable business practices; and a partnership with the You Can Play Project, which is committed to supporting the LGBT community and fighting homophobia in sports. The NHL received three 2014 Sports Business Awards: “Sports League of the Year,” “Sports Executive of the Year” recognizing Commissioner Gary Bettman, and “Sports Event of the Year” for the 2014 Bridgestone NHL Winter Classic®. For more information, visit NHL.com.

NHL, the NHL Shield, and the NHL All-Star Game logo, NHL Network name and logo, NHL Mobile and NHL Live are trademarks of the National Hockey League.  All Rights Reserved.

ABOUT THE NHLPA
The National Hockey League Players’ Association (NHLPA), established in 1967, is a labour organization whose members are the players in the National Hockey League (NHL). The NHLPA works on behalf of the players in varied disciplines such as labour relations, product licensing, marketing, international hockey and community relations, all in furtherance of its efforts to promote its members and the game of hockey. In 1999, the NHLPA launched the Goals & Dreams fund as a way for the players to give something back to the game they love. Over the past 15 years, more than 70,000 deserving children in 32 countries have benefited from the players’ donations of hockey equipment. NHLPA Goals & Dreams has donated more than $22-million to grassroots hockey programs, making it the largest program of its kind. For more information on the NHLPA, please visit www.nhlpa.com.

NHLPA, National Hockey League Players’ Association and the NHLPA logo are trademarks of the NHLPA. © NHLPA.

ABOUT GOPRO, INC. (NASDAQ:GPRO)
GoPro, Inc. is transforming the way consumers capture, manage, share and enjoy meaningful life experiences. We do this by enabling people to self-capture engaging, immersive photo and video content of themselves participating in their favorite activities. Our customers include some of the world’s most active and passionate people. The quality and volume of their shared GoPro content, coupled with their enthusiasm for our brand, virally drives awareness and demand for our products.

What began as an idea to help athletes self-document themselves engaged in their sport has become a widely adopted solution for people to self-document themselves engaged in their interests, whatever they may be. From extreme to mainstream, professional to consumer, GoPro has enabled the world to capture and share its passions. And in doing so the world, in turn, is helping GoPro become one of the most exciting and aspirational companies of our time.

For more information, visit www.gopro.com or connect with GoPro on YouTube, Twitter, Facebook, Pinterest or LinkedIn.

GOPRO, HERO, the GOPRO logo, and the GoPro Be A HERO logo are trademarks or registered trademarks of GoPro Inc. in the United States and other countries.

(VTAE) Announces Pricing of Follow-on Public Offering of Common Stock

FORT WASHINGTON, Pa., Jan. 23, 2015  — Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the pricing of its follow-on public offering of 3,000,000 shares of its common stock at $11.90 per share. All shares of common stock to be sold in the offering are being offered by Vitae. Vitae has also granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock.

The offering is expected to close on or about January 28, 2015, subject to customary closing conditions.

Stifel, BMO Capital Markets and Piper Jaffray & Co. are acting as joint book-running managers and JMP Securities and Wedbush PacGrow Life Sciences are acting as co-managers for the offering.

A registration statement relating to the shares to be sold in the offering has been filed with the Securities and Exchange Commission, and was declared effective on January 22, 2015. The offering is being made only by means of a prospectus. Copies of the prospectus related to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415) 364-2720, email: syndprospectus@stifel.com; or from BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, telephone: (800) 414-3627, email: bmoprospectus@bmo.com; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, telephone: (800) 747-3924, email: prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

CONTACT: Investors:
         Vitae Pharmaceuticals, Inc.
         Richard S. Morris, CPA
         Chief Financial Officer
         (215) 461-2000
         rmorris@vitaerx.com

         or

         Westwicke Partners
         John Woolford
         (443) 213-0506
         john.woolford@westwicke.com

         or

         Media:
         6 Degrees PR
         Tony Plohoros
         (908) 940-0135
         tplohoros@6degreespr.com

(ARRY) Announces Agreement To Acquire ENCORAFENIB (LGX818)

– Array to receive global rights from Novartis to innovative BRAF inhibitor – – Novartis to conduct and/or substantially fund ongoing clinical studies, including COLUMBUS – – Agreement subject to Novartis-GSK transaction close – – Conference call to discuss transaction on January 23, 2015 at 9:00 am Eastern Time –

BOULDER, Colo., Jan. 23, 2015  — Array BioPharma Inc. (NASDAQ: ARRY) today announced that it has reached a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development.  This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals. Array previously announced a definitive agreement with Novartis to regain global rights to the Phase 3 MEK inhibitor binimetinib, the material terms of which remain in place following this agreement. In order to address competition concerns raised by the European Commission, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. The European Commission is expected to issue a decision regarding the Novartis-GSK transaction on January 28, 2015.

“Acquiring worldwide rights to encorafenib, an innovative late-stage oncology product, represents a tremendous opportunity for Array,” said Ron Squarer, Chief Executive Officer, Array BioPharma.  “There are currently eleven active encorafenib clinical trials, including the Phase 3 COLUMBUS trial in which encorafenib is being studied in combination with binimetinib for BRAF+ melanoma patients.  With rights to both encorafenib and binimetinib, Array would enhance its position to broadly develop and commercialize each product, as well as this MEK/BRAF combination, which may have differentiating advantages when compared to available therapies.”

Terms of the Agreement 

Upon satisfaction of all conditions and closing of the deal, Array will acquire global rights to encorafenib.  Other than a de minimis payment due to Novartis from Array, there are no milestone payments or royalties payable under this agreement by either party.  Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign or license to Array all patent and other intellectual property rights Novartis owns to the extent relating to encorafenib.  As part of the transaction, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib.  If Array is unable to find a suitable partner in the prescribed time period, a trustee would have the right to sell such European rights.

Novartis will conduct and fund the COLUMBUS trial through the earlier of June 30, 2016 or completion of last patient first visit.  At that time, Array will assume responsibility for the trial, while Novartis will reimburse Array for out-of-pocket costs along with 50% of Array’s full time equivalent (FTE) costs in connection with completing the COLUMBUS trial. Novartis is responsible for conducting all other encorafenib trials until their completion or transfer to Array for a defined transition period.  For all trials transferred to Array, Novartis will reimburse Array for out-of-pocket costs and 50% of Array’s FTE costs in connection with completing the trials.

Novartis will supply encorafenib for clinical and commercial use for up to 30 months after closing and will also assist Array in the technology and manufacturing transfer of encorafenib.  Novartis will also provide Array continued access to several Novartis pipeline compounds for use in currently ongoing combination studies, and possible future studies, including Phase 3 trials, with encorafenib. The effectiveness of the agreement is subject to the receipt of regulatory approvals and to the consummation of the Novartis-GSK transaction.

In addition, Array agreed to undertake to obtain certain third party consents or waivers necessary for Array to consummate the transactions under the Novartis Agreement.

Conference Call Information 

Array will hold a conference call on January 23, 2015 at 9:00 a.m. Eastern Time to discuss this announcement.  Ron Squarer, Chief Executive Officer, will lead the call.

Webcast, including Replay and Conference Call Slides: http://edge.media-server.com/m/p/ykxqbcwi/lan/en

About BRAF and Encorafenib

Raf is a key protein kinase in the RAS/RAF/MEK/ERK signaling pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis.  Inappropriate activation of this pathway through BRAF mutations has been shown to occur in many cancers, such as melanoma, colorectal and thyroid cancers. Encorafenib is a potent and highly selective small molecule BRAF inhibitor that targets a key enzyme in this pathway and has shown clinical activity in a Phase 1 study in advanced tumors including melanoma and metastatic colorectal cancer.  A Phase 3 trial with encorafenib in combination with binimetinib in BRAF+ melanoma (COLUMBUS) is actively enrolling patients.  In addition, encorafenib is being studied in ten other clinical trials, including BRAF+ colorectal cancer.

BRAF Colorectal Cancer

At the 2014 EORTC-NIC-AACR Symposium on Molecular Targets and Cancer Therapeutics, preliminary results of a Phase 1 study were presented that showed a combination of encorafenib, cetuximab, an EGFR inhibitor, and alpelisib, a PI3K pathway inhibitor, may be an effective treatment for patients with BRAF+ colorectal cancer.  For the Phase 1 study, which continues to enroll participants, patients with BRAF+ colorectal cancer were randomly assigned to receive encorafenib plus cetuximab with or without alpelisib.  Results showed that the two-drug combination produced an objective response rate of 23%, while nearly one third (32%) of patients treated with the three-drug combination achieved an objective response. In addition, the median progression-free survival was 3.7 months and 4.3 months for the two-drug and three-drug combination groups, respectively.  The researchers noted that the median progression-free survival times observed in this study are nearly double those for patients who have been treated with standard therapy in the past. Furthermore, the combination of drugs was generally well-tolerated among patients.  There are over 200,000 colorectal cancer patients in the U.S. and it is estimated that the BRAF mutation is found in approximately 12% of this population.

BRAF Melanoma

Interim results from a Phase 1b study with binimetinib and encorafenib were presented by Novartis at the 2013 International Myeloma Conference.  The study demonstrated a disease control rate (>stable disease) of 100%, and an overall response rate (>partial response) of 89%, including one complete response, in BRAF inhibitor naive melanoma patients.  In melanoma patients who had been previously treated with a BRAF inhibitor, the disease control rate was 64%.

Preliminary data from the Phase 1b study also indicate that binimetinib and encorafenib may be safely combined at the intended single-agent doses.  Unlike other BRAF inhibitor / MEK inhibitor combinations, in this study there were no febrile (fever) or photosensitivity events, and a low incidence of rash was reported to date.  There were no signs of increased toxicity with the combination versus single agent therapy, and the combination showed early signs that it may mitigate some of the on-target adverse events common with single-agent BRAF inhibitor therapy, including cutaneous toxicities, myalgia and arthralgia.

About MEK and Binimetinib 

MEK is a key protein kinase in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Inappropriate activation of this pathway has been shown to occur in many cancers, in particular through mutations in BRAF, KRAS and NRAS.  Binimetinib is a small molecule MEK inhibitor that targets a key enzyme in this pathway.  Three Phase 3 trials with binimetinib in advanced cancer patients continue to enroll: NRAS-mutant melanoma (NEMO), low-grade serous ovarian cancer (MILO) and BRAF-mutant melanoma (COLUMBUS).  NRAS-mutant melanoma represents the first potential indication for binimetinib, with a projected regulatory filing estimated in the first half of 2016.

About Array BioPharma 

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Six Phase 3 studies on Array invented drugs, binimetinib (partnered with Novartis) and selumetinib (partnered with AstraZeneca), are currently enrolling patients with cancer. For more information on Array, please go to www.arraybiopharma.com.

Forward-Looking Statement 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the closing of the transaction with Novartis, the timing of the completion or initiation of further development of encorafenib or binimetinib, expectations that the return of rights to encorafenib or binimetinib to Array and other events will occur that will result in greater value for Array, the receipt of regulatory approvals and the ability of Array to locate a suitable development and commercialization partner for encorafenib or binimetinib in Europe, the potential for the results of ongoing preclinical and clinical trials to support regulatory approval or the marketing success of encorafenib or binimetinib, future plans to progress and develop encorafenib or binimetinib, and our plans to build a commercial-stage biopharmaceutical company. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on Form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress our proprietary drugs; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with our dependence on third-party service providers to successfully conduct clinical trials within and outside the United States; our ability to achieve and maintain profitability and maintain sufficient cash resources; and our ability to attract and retain experienced scientists and management. We are providing this information as of January 23, 2015. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

(DWA) Implements New Strategic Plan To Restructure Feature Film Business

GLENDALE, Calif., Jan. 22, 2015  — DreamWorks Animation (NASDAQ: DWA) is implementing a new strategic plan to restructure its core feature animation business to ensure the consistent and profitable delivery of the high quality films that audiences have come to expect from the studio.  Following a full review of the business, the company will focus its feature production from three films per year down to two, maximize its creative talent and resources, reduce costs, and drive profitability.

Under the leadership of newly appointed Co-Presidents of Feature Animation Bonnie Arnold and Mireille Soria, the studio’s core feature animation production will now focus on six specific movies for the next three years – one original film and one sequel each year – including Kung Fu Panda 3 (March 18, 2016), Trolls (Nov. 4, 2016), Boss Baby (Jan. 13, 2017), The Croods 2 (Dec. 22, 2017), Larrikins (Feb. 16, 2018) and How to Train Your Dragon 3 (June 29, 2018). Captain Underpants, which will be produced outside of the studio’s pipeline at a significantly lower cost, is scheduled for release in 2017.  The company’s 2015 release, Home, will premiere domestically on March 27.

“The number one priority for DreamWorks Animation’s core film business is to deliver consistent creative and financial success,” said DreamWorks Animation Chief Executive Officer Jeffrey Katzenberg.  “I am confident that this strategic plan will deliver great films, better box office results, and growing profitability across our complementary businesses.”

The overall reduction of DreamWorks Animation’s feature production output will result in a loss of approximately 500 jobs across all locations and all divisions of the studio. DreamWorks expects to incur a pre-tax charge of approximately $290 million in connection with the restructuring and related items.  These costs are expected to be incurred primarily in the quarter ended December 31, 2014, with the remainder in 2015 and 2016.  The plan will result in total cash payments of approximately $110 million incurred primarily in 2015.  The restructuring plan is expected to be substantially complete by the end of 2015 and expected to result in annualized pre-tax cost savings of approximately $30 million in 2015, growing to roughly $60 million by 2017.

Conference Call Information
DreamWorks Animation will host a conference call to discuss today’s announcement at 1:45 p.m. (PT) / 4:45 p.m. (ET) on Thursday, Jan. 22, 2015. The call will be available via live webcast at www.dreamworksanimation.com. To join the conference call by phone, please dial (800) 230-1766 in the U.S. and (612) 332-0430 internationally and identify “DreamWorks Animation Restructures Core Feature Film Business” to the operator. A replay of the conference call will be available shortly after the call ends on Thursday, January 22, 2015. To access the replay, dial (800) 475-6701 in the U.S. and (320) 365-3844 internationally and enter 351097 as the conference ID number. Both the press release and archived webcast will be available on the Company’s website at www.dreamworksanimation.com.

About DreamWorks Animation
DreamWorks Animation (Nasdaq: DWA) creates high-quality entertainment, including CG animated feature films, television specials and series and live entertainment properties, meant for audiences around the world. The company has world-class creative talent, a strong and experienced management team and advanced filmmaking technology and techniques. DreamWorks Animation has been named one of the “100 Best Companies to Work For” by FORTUNE® Magazine for five consecutive years. In 2013, DreamWorks Animation ranked #12 on the list.  All of DreamWorks Animation’s feature films are produced in 3D. The Company has theatrically released a total of 30 animated feature films, including the franchise properties of Shrek, Madagascar, Kung Fu Panda, How to Train Your Dragon, Puss In Boots, and The Croods.

Additional Information
The Company is concurrently filing a Current Report on Form 8-K with the U.S. Securities and Exchange Commission describing the restructuring, as well as certain other charges that the Company expects to record during the quarter ended December 31, 2014.  A copy of this Form 8-K filing is available on the Company’s website at www.dreamworksanimation.com.

Caution Concerning Forward-Looking Statements
This document includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company’s plans and expectations regarding its recently announced restructuring plan as well as its beliefs and expectations concerning performance of our current and future releases and anticipated talent, directors and storyline for our upcoming films and other projects, constitute forward-looking statements. These statements are based on current expectations, estimates, forecasts and projections about the industry in which we operate and management’s beliefs and assumptions. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors, and other risks and uncertainties affecting the operation of the business of DreamWorks Animation SKG, Inc. These risks and uncertainties include: the timing and success of implementation of the restructuring plan, audience acceptance of our films, our dependence on the success of a limited number of releases each year, the increasing cost of producing and marketing feature films, piracy of motion pictures, the effect of rapid technological change or alternative forms of entertainment and our need to protect our proprietary technology and enhance or develop new technology. In addition, due to the uncertainties and risks involved in the development and production of animated feature projects, the release dates for the projects described in this document may be delayed. For a further list and description of such risks and uncertainties, see the reports filed by us with the Securities and Exchange Commission, including our most recent annual report on Form 10-K and our most recent quarterly reports on Form 10-Q. DreamWorks Animation is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

(CBMX) Miscarriage Analysis Test Now Offered by ReproSource, Inc.

CombiMatrix Services Available Through ReproSource’s National Laboratory Network

IRVINE, Calif., Jan. 22, 2015  — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that ReproSource, Inc., a nationally-recognized laboratory dedicated to fertility specialists and the patients they serve, is now offering CombiMatrix’s chromosomal microarray analysis (CMA) testing for miscarriage analysis. ReproSource, based just outside of Boston, Massachusetts, is an international clinical reference laboratory providing specialized diagnostic services for unexplained infertility, recurrent pregnancy loss and premature ovarian failure.

“We have found CombiMatrix’s quality service to their physicians and patients to be consistent with our approach,” said Charles Jenkins, Vice President of ReproSource. “We look forward to offering our nationwide network of fertility specialists and fertility centers the opportunity to use CombiMatrix’s test offerings to help their patients.”

Mark McDonough, Chief Executive Officer of CombiMatrix, said, “ReproSource has an outstanding reputation in the fertility testing industry, and we view this partnership as a noteworthy validation of the quality of our tests and the ancillary counselling services we provide in this important new market for us. As we expand our focus to the care of fertility patients, we are pleased to offer our high touch, high quality service to ReproSource and their client base while concurrently benefitting from ReproSource’s expertise and customer reach with reproductive endocrinologists.”

Miscarriage analysis testing, also called Products of Conception testing, is a subset of the overall prenatal testing market. It allows OB/GYN physicians, reproductive endocrinologists, fertility doctors and clinicians to better determine if there is a genetic cause for a miscarriage or other related event.

“Historically, unclear results from genetic testing of products of conception has been frequent, which makes diagnosing the cause of miscarriage difficult and frustrating for both clinicians and patients,” said Benjamin Leader, M.D., Ph.D., the Director of Clinical Research at ReproSource. “The type of genetic testing provided by CombiMatrix significantly increases the frequency with which we can provide reliable answers to our physicians and their patients.”

About ReproSource

ReproSource is a clinical reference laboratory and research organization that exists to provide clinicians and patients alike with the best solutions for fertility testing and education. ReproSource publishes some of the largest studies in the world related to fertility testing, and works both nationally and internationally with fertility experts to provide the best in patient care and clinical research. ReproSource continually works to refine research, validate results and update the fertility testing used for initial patient diagnostic evaluations. ReproSource empowers clinicians and patients to make the most informed decisions in the treatment of recurring pregnancy loss and unexplained infertility.

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in miscarriage analysis, prenatal testing and pediatric genetics, offering DNA‑based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (“FISH”) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “goal,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” “objective,” similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding the access to our services for ReproSource, Inc.’s physicians. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: use of our services by ReproSource patients; market acceptance of CMA as a superior method of molecular diagnostic testing; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests in both of our primary markets, develop and introduce new tests and related reports, optimize the reimbursements received for our testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, allow access to samples earlier in the testing continuum, steadily increase the size of our customer rosters in both developmental medicine and oncology; our ability to attract and retain a qualified sales force; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.

CONTACT: Company Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         (949) 753-0624

         Investor Contact:
         Robert Flamm, Ph.D.
         Russo Partners, LLC
         (212) 845-4226
         robert.flamm@russopartnersllc.com

         Media Contact:
         David Schull or Lena Evans
         Russo Partners LLC
         (212) 845-4271
         (212) 845-4262
         david.schull@russopartnersllc.com
         lena.evans@russopartnersllc.com

(CLIR) Announces Agreement to Install Duplex Technology in Third Oil & Gas Operation

New refinery customer joins Tricor, LLC and Aera Energy LLC — looks to ClearSign to reduce environmental impact at California refinery while improving bottom line.

SEATTLE, Jan. 22, 2015  — ClearSign Combustion Corporation (NASDAQ: CLIR), an emerging leader in combustion and emissions control technology for industrial, commercial and utility markets, announced today the signing of a field validation agreement with a California-based refinery to retrofit a three-burner, 12 MMBtu/hr process heater with its proprietary Duplex™ technology.

The agreement comes in the wake of last week’s announcement of a field validation with Tricor Refining, LLC to retrofit a 15 MMBtu/hr vertical cylindrical heater.

ClearSign is also conducting continuous operation testing of Duplex technology in a 62.5 MMBtu/hr steam generator operated by Aera Energy LLC. While additional testing is ongoing, ClearSign reports that tests below the maximum firing rate have yielded encouraging results including NOx emissions that satisfy the San Joaquin Valley Air Quality Management District’s Rule 4320.

The new refinery customer, announced today, selected ClearSign’s Duplex technology for its unique ability to safely and cost-effectively lower NOx emissions to below 6 PPM in southern California — a region with among the most stringent air quality standards in the world — without the need for more expensive flue gas recirculation (FGR) or selective catalytic reduction (SCR) after-treatment. Unlike current ultra-low NOx burners, ClearSign’s Duplex technology achieves this emissions performance without the potential limits to furnace capacity.

“This agreement is another example of the increasing demand for ClearSign’s transformative Duplex technology and its unique ability to solve the critical environmental and operational challenges our refinery customers are facing,” said Stephen Pirnat, CEO of ClearSign.

ClearSign will again collaborate in this project with Advanced Combustion and Process Controls, Inc., who will oversee the installation.

About ClearSign Combustion Corporation

ClearSign Combustion Corporation designs and develops technologies that aim to improve key performance characteristics of combustion systems including energy efficiency, emissions control, fuel flexibility and overall cost effectiveness. Our patent-pending Duplex™ and Electrodynamic Combustion Control™ platform technologies improve control of flame shape and heat transfer and optimize the complex chemical reactions that occur during combustion in order to minimize harmful emissions. For more information about the Company, please visit www.clearsign.com

Cautionary note on forward-looking statements
This press release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events that are based on management’s belief, as well as assumptions made by, and information currently available to, management. While we believe that our expectations are based upon reasonable assumptions, there can be no assurances that our goals and strategy will be realized. Numerous factors, including risks and uncertainties, may affect our actual results and may cause results to differ materially from those expressed in forward-looking statements made by us or on our behalf. Some of these factors include the acceptance of existing and future products, the impact of competitive products and pricing, general business and economic conditions, and other factors detailed in our Quarterly Report on Form 10-Q and other periodic reports filed with the SEC. We specifically disclaim any obligation to update or revise any forward-looking statement whether as a result of new information, future developments or otherwise.

(NNVC) Ships anti-Ebola Drug Candidates For Testing

WEST HAVEN, Conn., Jan. 22, 2015  — NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”), a nanomedicine company developing anti-viral drugs, reported that it has shipped several anti-Ebola nanoviricide® drug candidates to a hi-security bio-containment facility in the US that is capable of performing evaluation of these drug candidates in the required biological safety level 4 (BSL-4) environment.

The Company has designed these novel anti-Ebola broad-spectrum drug candidates such that they are expected to continue to work in spite of mutations in the field.

Using NanoViricides’s rapid design platform, it took only 4 months from design to synthesis of the multiple drug candidates. These candidates are designed to attack the Ebola virus at the site on the virus that does not change in spite of mutations because the virus uses this site to bind to its cognate receptor in human cells, namely NPC1. Some of the candidates are designed to attack another conserved site on the Ebola virus that is thought to be involved in the fusion process of the virus required for it to successfully enter the cell.

The Company already has the capability of producing sufficient quantities of a successful anti-Ebola drug in its new cGMP-capable facility in Shelton, CT, for combating the current Ebola epidemic. This pilot scale manufacturing facility will be able to supply the successful nanoviricides drug candidate in quantities needed for the treatment of patients in West Africa infected with the Ebola virus. NanoViricides, Inc. is one of the very few companies that has the ability produce its drug candidates at this full-response scale.

The Company had previously developed anti-Ebola drug candidates that demonstrated the validity and potential of the Company’s approach, based on cell culture and animal testing conducted at USAMRIID in 2008-2009. At that time, the cognate receptor of the Ebola virus was still unknown and the Company used certain heuristic approaches to design potential drug candidates for the purpose of validating our approach. The Company had to de-prioritize this development in order to focus on the development of its lead drug candidate, Injectable FluCide™, for treatment of hospitalized patients with influenza. The current outbreak in Africa has unequivocally demonstrated the need for an effective, broad-spectrum, anti-Ebola therapeutic. NanoViricides engaged into the anti-Ebola drug development with the highest priority in order to respond to this challenge recently.

About NanoViricides: ”
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

(EGLT) Abuse-Deterrent Morphine Egalet-001, Positive Top-Line Results

Egalet-001 Met Primary Endpoint of Reduced Drug Liking Compared to MS Contin(R)

WAYNE, Pa., Jan. 22, 2015  — Egalet Corporation (Nasdaq:EGLT) (“Egalet”) today announced positive results from a Category 3 human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. The clinical HAL study demonstrated that in nondependent, recreational opioid users, the abuse potential of manipulated Egalet-001 taken orally was significantly lower than that for manipulated MS Contin (morphine sulfate controlled-release).

“This is the first Category 3 clinical human abuse liability study for Egalet’s Guardian™ Technology,” said Jeffrey Dayno, MD, chief medical officer at Egalet. “The study results demonstrate the robustness of Egalet’s differentiated technology, which is based not only on the principles of formulation and matrix design, but also on its unique manufacturing process that employs injection molding. These clinical data expand the abuse-deterrent profile of Egalet-001 which, in Category 1 studies, has shown strong abuse-deterrent characteristics by demonstrating resistance to common and rigorous methods of physical and chemical manipulation in a differentiated approach without introducing an additional pharmacologic agent.”

This Category 3 abuse-deterrent HAL study was conducted in accordance with the FDA draft guidance on Abuse-Deterrent Opioids: Evaluation and Labeling (January 2013). It was a single-center, randomized, double-blind, double-dummy, four-way crossover study which assessed the abuse potential of Egalet-001 versus MS Contin in 38 nondependent, recreational opioid users when taken orally. The primary objective was to compare the relative abuse potential of intact and manipulated formulations of Egalet-001 versus manipulated MS Contin. Since Egalet-001 is extremely hard and difficult to chew, the manipulation of the product involved a series of maneuvers using different household tools to try and reduce the particle size to maximally defeat the tablet. This procedure was based on the outcome of the first phase, physical tampering, of the Category 1 abuse-deterrent studies for Egalet-001.

A few highlights from the study include:

• On the primary endpoint of drug liking as measured by Emax, the score for manipulated Egalet-001 was significantly lower than the Emax for manipulated MS Contin (p < 0.007);
• There was no statistical difference on drug liking scores (Emax) between intact and manipulated Egalet-001, indicating that even after significant manipulation, Egalet-001 retains its abuse-deterrent characteristics;
• The corresponding pharmacokinetic (PK) data from this study demonstrated a higher maximum plasma concentration (Cmax) and shorter time to maximum plasma concentration (Tmax) for manipulated MS Contin compared to manipulated Egalet-001; and,
• The ‘Abuse Quotient,’ which is defined as the Cmax/Tmax, for each of the treatment arms, was as follows:
  • 5.7 for intact Egalet-001
  • 16.4 for manipulated Egalet-001 and
  • 45.9 for manipulated MS Contin

“The data from this oral human abuse liability study demonstrate a clinically relevant decrease in drug liking for Egalet-001 compared to MS Contin when manipulated and taken orally,” said Lynn Webster, MD, principal investigator of the study and vice president scientific affairs, PRA International. “These clinical results, plus the difficulty that I have observed trying to defeat the Egalet-001 tablets in preparation for the study, suggest that Egalet-001 shows real promise as an abuse-deterrent, extended-release morphine product candidate to help address the ongoing challenge of opioid misuse, abuse, overdose and death.”

In addition to this Category 3 HAL study, Egalet presented positive results from Category 1 studies for Egalet-001 last year at PainWeek and will share the results from additional abuse-deterrent studies later this year.

About Egalet

Egalet, a fully integrated commercial specialty pharmaceutical company, is focused on developing, manufacturing and marketing innovative pain treatments. The Company has two approved products: OXAYDO (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting, for the management of acute and chronic moderate to severe pain where an opioid is appropriate, and SPRIX® (ketorolac tromethamine) Nasal Spray, a non-steroidal anti-inflammatory drug (NSAID), indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level. In addition, using Egalet’s proprietary Guardian™ Technology, the Company is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet’s Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Full prescribing information for OXAYDO and SPRIX and additional information on Egalet can be found at www.egalet.com.

Safe Harbor

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of our clinical trials; our ability to obtain regulatory approval of our product candidates; competitive factors; general market conditions; and other risks factors described in Egalet’s filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

CONTACT: Investor and Media Contact:
         BiotechComm
         E. Blair Clark-Schoeb
         Tel: 917-432-9275
         Email: blair@biotechcomm.com

(ALDR) Announces Exercise in Full of Option to Purchase Additional Shares

BOTHELL, Wash., Jan. 22, 2015  — Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 900,000 shares of common stock. The closing of the option exercise occurred on January 22, 2015. Gross proceeds from the offering of an aggregate of 6,900,000 shares at a public offering price of $29.50 per share, before underwriting discounts and commissions and offering expenses, were approximately $203.6 million.

Credit Suisse, Leerink Partners and Wells Fargo Securities acted as joint book-running managers for the offering. Sanford C. Bernstein acted as co-manager for the offering.

The Securities and Exchange Commission declared effective a registration statement relating to the offering of these securities on January 8, 2015. The offering is being made only by means of a prospectus, which is part of the effective registration statement. A copy of the prospectus relating to the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York, 10010, and by phone at 1-800-221-1037 or by email at newyork.prospectus@credit-suisse.com; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, and by phone at 1-800-808-7525 or by email at syndicate@leerink.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York, 10152, or by email at cmclientsupport@wellsfargo.com, or by phone at 1-800-326-5897.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

CONTACT: Media Contacts:

         David Schull or Andrea Flynn, Ph.D.
         Russo Partners
         (212) 845-4271
         (646) 942-5631
         david.schull@russopartnersllc.com
         andrea.flynn@russopartnersllc.com

         Investor Relations Contacts:

         Sarah McCabe
         Stern Investor Relations, Inc.
         (212) 362-1200
         sarah@sternir.com

(AMD) FirePro(TM) Exceptional Performance on Next Generation HP ZBook Mobile Workstations

AMD FirePro(TM) M4150 and M4170 Mobile Professional Graphics Now Available on New HP ZBook Mobile Workstations Delivering Outstanding Quality, Performance and Innovation for Professional Users

SUNNYVALE, CA–(Jan 21, 2015) – AMD (NASDAQ: AMD) today announced that second-generation HP ZBook 14 G2 and 15u G2 Mobile Workstations feature AMD FirePro™ M4150 and AMD FirePro™ M4170 mobile professional graphics models, providing users with speed, quality and creativity on the go. AMD FirePro™ professional graphics are compliant with the latest industry standards enabling users to take full advantage of applications from companies including Adobe®, Autodesk, Avid, Dassault Systèmes, ESRI, Siemens, and many others.

AMD FirePro mobile professional graphics are powered by the award-winning AMD Graphics Core Next (GCN) Architecture¹ and are especially designed to enable outstanding performance for professional applications in a wide variety of work environments for many computer-aided design (CAD) and digital media applications.

“AMD and HP have combined efforts to enable mobile workstation users with leading-edge technologies with results that matter for designing, engineering, and creating,” said David Cummings, senior director and general manager, Professional Graphics at AMD. “HP mobile workstation users can benefit from quality driver support and certified ISV applications for a stable and reliable platform that redefine mobile workstation performance while enabling users to do more.”

“Our customers demand productivity features for their mission-critical projects especially for computer-aided design and content creation,” said Jeff Wood, vice president, Worldwide Product Management, Commercial Solutions Business Unit, HP. “We know our mobile workstation customers can rely on AMD FirePro mobile professional graphics for the performance they demand backed with robust driver and application support.”

AMD FirePro professional graphics are now available — from high end to entry level — on the HP ZBook 17 G2, HP ZBook 15 G2, HP ZBook 15u G2 and HP ZBook 14 G2. Based on the award winning desktop AMD FirePro™ W-series professional graphics, the AMD FirePro™ M-series mobile professional graphics offers:

• Desktop class workstation performance On-the-Go,
• AMD FirePro mobile professional graphics are built for performance supported by high-quality software drivers that are finely tuned to work optimally with leading workstation applications featuring OpenCL™, and
• Intelligent Power Features offer unique power monitoring and management technologies to help deliver great battery life to mobile workstations:
  • AMD Enduro™ Technology¹ switchable graphics mode allows AMD FirePro mobile professional graphics to optimize battery life based on workload requirements,
  • AMD PowerTune Technology¹ intelligently monitors and manages the power draw to enable higher clock speeds, which helps provide improved performance, and,
  • AMD ZeroCore Power¹ allows AMD FirePro GPU to consume virtually no power when in idle state.

Supporting Resources

• Learn more about AMD FirePro mobile professional graphics
• Learn more about AMD FirePro professional graphics
• Learn more about applications certified for AMD FirePro
• Become a fan of AMD on Facebook
• Follow AMD professional graphics on Twitter — @AMDFirePro

About AMD
AMD (NASDAQ: AMD) designs and integrates technology that powers millions of intelligent devices, including personal computers, tablets, game consoles and cloud servers that define the new era of surround computing. AMD solutions enable people everywhere to realize the full potential of their favorite devices and applications to push the boundaries of what is possible. For more information, visit www.amd.com.

AMD, the AMD Arrow logo and FirePro are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners. OpenCL and the OpenCL logo are trademarks of Apple Inc. used by permission by Khronos.

¹ The GCN Architecture and its associated features (AMD Enduro™, AMD PowerTune, and AMD ZeroCore Power technology,) are exclusive to the AMD FirePro™ M4150 and M4170mobile professional graphics. Not all technologies are supported in all system configurations — check with your system manufacturer for specific model capabilities.

(EXXI) to Host The Oil & Services Conference™ 13, February 18-19, 2015, in San Francisco

DENVER, Jan. 21, 2015  — EnerCom, Inc. will host The Oil & Services Conference™ 13 (TOSC 13) from February 18-19, 2015, at the Omni San Francisco Hotel. Institutional investors, energy research analysts, and oil and gas investors can register to attend, and find the work-in-progress presenter schedule at The Oil & Services Conference™ website.

EnerCom’s The Oil & Services Conference™ 13 is a well-attended major investment forum featuring presentations from E&P and OilService companies, energy research analysts, and industry thought-leaders. Measurable benefits for attending institutional investors include:

• ACCESS. Investors receive access to more than 35 oil and gas executives and analysts, gaining insight to their knowledge and insight on key industry issues and emerging trends. EnerCom works with presenting company management teams arranging one-on-one meetings with the attending institutional investors and research analysts during the Conference.
• ANALYSIS. To complement the 35 oil and gas presenters, attendees will hear presentations from industry thought leaders such as J. Marshall Adkins, director of energy research at Raymond James, Art Hogan, chief market strategist at Wunderlich Securities, Tom Petrie, founder of Petrie Partners, and Roger Read, senior energy analyst at Wells Fargo Securities.
• INSIGHT. TOSC 13 is the first major investment forum for E&P and OilService companies to present their 2015 outlooks. Luncheon presentations, as well as evening networking events, present more opportunities to gain perspective and exchange information. EnerCom will report company highlights and new developments in real-time using the Twitter hash-tag #TOSC13.
• IDEAS. Public and private oil & gas E&P and OilService Companies will present over the two days providing the investment professional new ideas on investment opportunities. A continuous series of 25-minute presentations, followed by 50-minute breakout sessions for Q&A will run from February 18-19, 2015.
• DISTRIBUTION. EnerCom wants to know how leaders are thinking about their companies and will interview executives and analysts during TOSC13. These interviews, as well as questions asked during breakout sessions will be posted after the conference on EnerCom’s Oil & Gas 360® website.

About The Oil & Services Conference™ 13

Founded in 2003 by EnerCom, The Oil & Services Conference™ annually provides access, analysis, insight and ideas to company management teams and investment professionals focused on the global oil and gas industry. Global conference sponsors of TOSC 13 are Credit Agricole Corporate and Investment Bank, Netherland, Sewell & Associates, Preng & Associates, Hein & Associates, Wunderlich Securities, Fifth Third Bank and DNB Bank ASA.

About EnerCom, Inc.

Founded in 1994, EnerCom, Inc. is a nationally recognized management consultancy firm advising and serving energy-centric clients on corporate strategy, asset valuations, investor relations, media and corporate communications and visual communications design.  The Company’s professionals have more than 170 years of industry and business experience and a proven track record of success. Headquartered in Denver, EnerCom uses the team approach for delivering its wide range of services to public and private companies, large and small, operating in the global exploration and production, OilService, capital markets, and associated advanced-technology industries. The Company annually hosts two oil and gas investment conferences:

• The Oil & Services Conference™ 13 – San Francisco, California – February 18-19, 2015
• The Oil & Gas Conference® 20 – Denver, Colorado – August 16-20, 2015

EnerCom’s Oil & Gas 360® is a daily source of news and analysis from the professionals at EnerCom, Inc. The website oilandgas360.com is dedicated to the people, technologies, transactions, trends, macro-economic analysis and other forces impacting commodity prices and the oil and gas industry as a whole.

For more information about EnerCom, its services, Conferences and Oil & Gas 360® please call +303-296-8834.

About Credit Agricole Corporate and Investment Bank

Credit Agricole Corporate and Investment Bank is the corporate and investment banking arm of the Credit Agricole Group, the world’s eighth largest bank by total assets (The Banker, July 2014).  Credit Agricole CIB offers its clients a comprehensive range of products and services in capital markets, brokerage, investment banking, structured finance, corporate banking, and international private banking.

The Bank provides support to clients in large international markets through its network, with a presence in major countries in Europe, the Americas, Asia and the Middle East.

With headquarters in New York City, and U.S. offices in Houston and Chicago, Credit Agricole CIB Americas offers its corporate and institutional clients financial products and services and made-to-order structuring, origination and distribution, through both its banking unit Credit Agricole CIB, and the full service broker-dealer Credit Agricole Securities (USA) Inc., which is a member of the NYSE and NASD.  Credit Agricole CIB is also present in Montreal, Canada, and in Latin America with offices in Argentina, Brazil, and Mexico.

The Energy Industry represents the single largest concentration of industry exposure at Credit Agricole Corporate and Investment Bank, whose specialty focus dates back over 100 years. Our Energy practice for North America, located in Houston, focuses on all segments of the business and covers it on a truly global basis.

For more information, visit www.ca-cib.com.

About Netherland, Sewell & Associates, Inc.

Netherland, Sewell & Associates, Inc. (NSAI) was founded in 1961 to provide the highest quality engineering and geological consulting to the petroleum industry.  Today they are recognized as the worldwide leader of petroleum property analysis to industry and financial organizations and government agencies.  With offices in Dallas and Houston, NSAI provides a complete range of geological, geophysical, petrophysical, and engineering services and has the technical experience and ability to perform these services in any of the onshore and offshore oil and gas producing areas of the world. They provide reserves reports and audits, acquisition and divestiture evaluations, simulation studies, exploration resources assessments, equity determinations, and management and advisory services.  For a complete list of services or to learn more about Netherland, Sewell & Associates, Inc. please visit www.netherlandsewell.com.

For more information about NSAI, call C.H. (Scott) Rees, Chief Executive Officer, at 214-969-5401 or send an email to info@nsai-petro.com.

About Preng & Associates

Preng & Associates, founded in 1980, is the only retainer-based, international executive search firm specializing solely in the energy industry.  Its number one priority is to assist clients with their executive selection, organization development, and human resource needs by providing the highest quality service. Preng’s record of accomplishment is directly attributable to their experienced staff, worldwide network of industry contacts, proven search methodology, and high standards of professionalism.  Preng has conducted over 3000 searches for board, executive, management, and professional positions in its 34-year history and has the highest success and repeat client track record.

Preng’s practice is based on the premise that the search process is most effective when conducted by professionals with significant search industry experience.  The company has earned a reputation for combining professional search disciplines with an in-depth industry and market understanding and has succeeded in some of the industry’s most challenging and high-profile searches. Preng’s international reach allows it to effectively conduct global engagements; and as a member of the Association of Executive Search Consultants, Preng practices and promotes its high standards of conduct and professionalism.

For more information about Preng & Associates, contact Charles Carpenter, Partner at 713-243-2610 or ccarpenter@preng.com. 

About Hein & Associates

Hein & Associates LLP is recognized as a leading accounting and advisory firm where its people and clients share knowledge, thrive in a culture of teamwork, and build long-term relationships deeply rooted in integrity. Hein serves public and private companies in a variety of industries across the country from our offices in Denver, Dallas, Houston, and Orange County. We also serve clients globally through our alliance with associations of independent accounting firms around the world.

Hein is ranked among the Top 25 auditors serving SEC registrants, and Accounting Today lists Hein among the nation’s overall Top 100 accounting and advisory firms. Hein has been named to Inside Public Accounting’s “Best of the Best Firms” list, honoring only 50 firms for their management and superior operational performance.

For more information, please contact Brian Mandell-Rice, Managing Partner, at bmandell-rice@heincpa.com, 303.298.9600 or visit www.heincpa.com.

About Wunderlich Securities

Established in 1996 in Memphis, TN, Wunderlich Securities, a full-service brokerage firm, is committed to providing a comprehensive range of professional products and services to meet the needs of individual investors as well as corporations and institutions. The Firm offers financial advisory, brokerage, equity research and investment banking services. Fixed Income broker services are provided through Wunderlich Securities Fixed Income Capital Markets and WunTrade divisions of Wunderlich Securities. The firm operates in 26 offices across 15 states and has more than 450 associated professionals.

For more information, please contact R. Kevin Andrews, Managing Director, Investment Banking, at (713) 403-3979 or visit www.wunderlichsecurities.com.

About Fifth Third Bancorp

Fifth Third Bancorp is a diversified financial services company headquartered in Cincinnati, Ohio.  The Company has $130 billion in assets and operates 17 affiliates with 1,320 full-service Banking Centers, including 104 Bank Mart® locations, most open seven days a week, inside select grocery stores and 2,586 ATMs in Ohio, Kentucky, Indiana, Michigan, Illinois, Florida, Tennessee, West Virginia, Pennsylvania, Missouri, Georgia and North Carolina. Fifth Third operates four main businesses: Commercial Banking, Branch Banking, Consumer Lending, and Investment Advisors. Fifth Third also has a 25% interest in Vantiv Holding, LLC. Fifth Third is among the largest money managers in the Midwest and, as of December 31, 2013, had $302 billion in assets under care, of which it managed $27 billion for individuals, corporations and not-for-profit organizations. Investor information and press releases can be viewed at www.53.com. Fifth Third’s common stock is traded on the NASDAQ® Global Select Market under the symbol “FITB.”  Fifth Third Bank was established in 1858.  Member FDIC.

For more information, please contact Richard C. Butler, Senior Vice President at (713) 401-6101.

About DNB Bank ASA

DNB is Norway’s largest financial services group and one of the largest in the Nordic region in terms of market capitalization. The Group offers a full range of financial services, including loans, savings, advisory services, insurance and pension products for retail and corporate customers. The Corporate Banking department is focused on relationship lending within the oil & gas and power & renewables sectors, primarily serving investment grade customers based in North America. As many of these customers have a large global footprint, DNB Houston works closely with the energy teams in London, Norway, Singapore and Santiago to service customers’ needs.

For more information, please visit https://www.dnb.no/en/corporate-and-institutions.

(FWM) to Report Third Quarter Fiscal Year 2015 Financial Results

NEW YORK, Jan. 21, 2015  — Fairway Group Holdings Corp. (“Fairway”) (Nasdaq:FWM), the parent company of Fairway Market, today announced that the Company will report financial results for the third fiscal quarter ended December 28, 2014 on Thursday, February 5, 2015 after the market closes.

The conference call is scheduled to begin at 4:30 p.m.  The call and slide presentation will be available in the Investor Relations section of the Company’s website at http://investors.fairwaymarket.com and will be archived online for a short period thereafter. In addition, listeners may dial (877) 353-0039 to access the live call. A telephonic playback will be available after the call through Thursday, February 19, 2015. Participants can dial (855) 859-2056 and enter the conference passcode 71381667 to hear the playback.

About Fairway Market

Fairway Market is a growth-oriented food retailer offering customers a differentiated one-stop shopping experience “Like No Other Market”®. Fairway has established itself as a leading food retailing destination in the Greater New York City metropolitan area, with stores that emphasize an extensive selection of fresh, natural and organic products, prepared foods and hard-to-find specialty and gourmet offerings, along with a full assortment of conventional groceries. Fairway is headquartered in New York, New York. See www.fairwaymarket.com for more information.

CONTACT: Fairway Group Holdings Corp.
         Nicholas Gutierrez
         Director of Finance & Investor Relations
         (646) 616-8103
         nicholas.gutierrez@fairwaymarket.com

(FORD) Appointment of Interim CEO Michael Luetkemeyer, Chairman Terence Bernard Wise

WEST PALM BEACH, Fla., Jan. 21, 2015  — Forward Industries, Inc. (Nasdaq:FORD) today announced a leadership transition under which, effective January 15, 2015, Robert Garrett, Jr. voluntarily resigned as Chief Executive Officer. Current director Michael Luetkemeyer will serve as the Company’s interim CEO, effective immediately. In addition, the Board of Directors has also determined to elect Terence Bernard Wise as Chairman of the Company.

Commenting on his appointment, Mr. Luetkemeyer said, “I greatly appreciate the confidence the Board has placed in me during this pivotal time for the Company. I am delighted to be able to take up the reins at Forward and oversee its ongoing transformation as we work to unlock its full potential. Forward has an incredibly strong foundation that reflects the quality of its products and the dedication of its employees. I look forward to working to continue providing our customers with the excellence they have come to expect from us.”

Mr. Luetkemeyer, has extensive executive experience in the medical device industry, Forward’s largest market, having served as the Chief Financial Officer of TranS1, Inc., a NASDAQ-listed medical device company from April 2007 through March 2010. Prior to his appointment to interim Chief Executive Officer at Forward, he worked as an independent consultant in the areas of strategic planning, financial management and infrastructure development. Prior to serving as CFO of TranS1, Mr. Luetkemeyer served as Senior Vice President and Chief Financial Officer of Micromuse, Inc., a NASDAQ-listed provider of network management software, from October 2001 to May 2006. He also served as a member of Micromuse’s board of directors from January 2003 through February 2005, and as its interim CEO during 2003. Prior to Micromuse, Mr. Luetkemeyer also served as Chief Financial Officer at NASDAQ-listed companies Rawlings Sporting Goods and Electronic Retailing Systems. Mr. Luetkemeyer has held a variety of senior finance positions throughout his career, including more than 10 years with General Electric, where he served with GE Aerospace, GE Semiconductor, and GE Plastics.

Speaking on behalf of the Board, Mr. Luetkemeyer added, “The newly constituted Board is prepared and excited to immediately begin working to put Forward back on track for long-term value creation for all shareholders. To that end, we are proud to announce that Terence Bernard Wise will serve as Forward’s Chairman. Mr. Wise’s perseverance throughout a hard-fought proxy contest is a testament to his commitment to Forward and its shareholders. We are certain he will provide the strong and confident leadership Forward needs as we work towards a shared goal of excellence for Forward.”

Mr. Wise commented, “Over the course of the past year, I have been immensely grateful for the support of the Forward community and its shareholders in our efforts to reclaim our company. I am honored to now be entrusted with the opportunity to lead Forward and work to enhance value for all of Forward’s stakeholders, including its shareholders, employees, and customers. On behalf of the Board, we all look forward to commencing our hard work inside the boardroom.”

About Forward Industries, Inc.

Incorporated in 1962, and headquartered in West Palm Beach, Fla., Forward Industries is a global designer and distributor of mobile device cases and accessories. Forward Industries’ products can be viewed online at www.forwardindustries.com.

Forward-Looking Statements

In addition to the historical information contained herein, this press release contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that reflect the Company’s current expectations and projections about its future results, performance, prospects and opportunities. The Company has tried to identify these forward-looking statements by using words such as “may,” “should,” “expect,” “hope,” “anticipate,” “believe,” “intend,” “plan,” “estimate” and similar expressions. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties and other factors that could cause its actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.  No assurance can be given that the actual results will be consistent with the forward-looking statements. Investors should read carefully the factors described in the “Risk Factors” section of the Company’s filings with the SEC, including the Company’s Form 10-K for the year ended September 30, 2014 for information regarding risk factors that could affect the Company’s results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

CONTACT: Benjamin Jones
         561-465-0071
         bjones@forwardindustries.com

(REXX) Declares Dividend on Series A Preferred Depository Shares

STATE COLLEGE, Pa., Jan. 21, 2015  — Rex Energy Corporation (Nasdaq:REXX) today announced that the Board of Directors of Rex Energy Corporation has declared a quarterly cash dividend of $150.00 per share on its 6.0% Series A convertible perpetual preferred stock. As a result, on February 15, 2015, a dividend of $1.50 per depository share, each representing a 1/100^th interest in a share of Series A convertible perpetual preferred stock will be paid to holders of record at the close of business on February 1, 2015.

Forward-Looking Statements

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Forward-looking statements are based on current beliefs and expectations and involve certain assumptions or estimates that involve various risks and uncertainties, such as financial market conditions, changes in commodities prices and the other risks discussed in detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 and other subsequent filings with the Securities and Exchange Commission. Readers should not place undue reliance on any such forward-looking statements, which are made only as of the date hereof. Rex Energy has no duty, and assumes no obligation, to update forward-looking statements as a result of new information, future events or changes in the Company’s expectations.

About Rex Energy Corporation

Rex Energy is headquartered in State College, Pennsylvania and is an independent oil and gas exploration and production company operating in the Appalachian and Illinois Basins within the United States. The company’s strategy is to pursue its higher potential exploration drilling prospects while acquiring oil and natural gas properties complementary to its portfolio.

CONTACT: Mark Aydin
         Manager, Investor Relations
         (814) 278-7249
         maydin@rexenergycorp.com

(CNIT) Announces Contract for Installation of 20,000

New Media Elevator Terminals in Guangdong Province

SHENZHEN, China, Jan. 21, 2015  — China Information Technology, Inc. (the “Company” or “CNIT”) (Nasdaq GS: CNIT), a leading provider of integrated cloud-based platform, exchange, and big data solutions to the Chinese new media industry, today announced that the Company was selected by a leading advertising agency to install 20,000 cloud-based new media elevator terminals in Guangdong province. Depending on specific terminals, revenues from these installations will be recognized through one-time terminal sales and recurring monthly platform service fees as well as through recurring monthly fees that include terminal rental and platform service fees. The terminals are expected to be installed by the end of 2017.

Mr. Guangyuan Zong, Chief Marketing Officer of CNIT, stated, “We are pleased to bring our advanced new media elevator terminals to major cities of Guangdong province. Winning this contract demonstrates that our new media elevator terminals and online platform continue to gain traction among customers. We look forward to further expanding our market share in 2015.”

The Company’s new media elevator terminals show advertisements and public information on 21.5-inch wall-mounted displays with high-definition digital output. The multi-functional system enables advertising agencies to remotely manage all of their content. Through the CNIT Cloud-App-Terminal elevator platform, the same terminals also enhance elevator safety via the transmission of technical data on elevator operation to property management, elevator safety supervision and maintenance bureaus on a real-time basis.

The CNIT new media elevator terminals will be installed in the following major cities: Foshan, Zhongshan, Dongguan, Yunfu, Zhaoqing, Zhuhai and Jiangmen, which together constitute a key part of the Pearl River Delta Economic Zone with a total population of 30 million.

About China Information Technology, Inc.

China Information Technology, Inc. (CNIT) is on a mission to make advertising accessible and affordable for businesses of all sizes. CNIT is a leading provider of integrated cloud-based platform, exchange, and big data solutions to the Chinese new media industry. Its Internet ecosystem enables all participants of the new media community to efficiently promote brands, disseminate knowledge, and exchange resources. Through continuous innovation, CNIT is leveraging its proprietary Cloud-Application-Terminal technology to level the competitive landscape in the new media industry and deliver value for its shareholders, employees, customers, and the community. To learn more, please visit www.chinacnit.com.

Safe Harbor Statement

This press release may contain certain “forward-looking statements” relating to the business of China Information Technology, Inc., and its subsidiaries and other consolidated entities. All statements, other than statements of historical fact included herein, are “forward-looking statements” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, often identified by the use of forward-looking terminologies such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company and its subsidiaries and other consolidated entities or persons acting on their behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For further information, please contact:

China Information Technology, Inc.
Tiffany Pan
Tel: +86 755 8370 4767
Email: ir@chinacnit.com
www.chinacnit.com

Grayling
Shiwei Yin
Investor Relations
Tel: +1.646.284.9474
Email: cnit@grayling.com

(ALDX) Announces $2.0 Million Private Placement

LEXINGTON, Mass., Jan. 20, 2015  — Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement with a leading financial services company to raise approximately $2.0 million in a private placement of common stock and a warrant to purchase common stock (the Purchase Agreement). Aldeyra plans to use the proceeds for its upcoming Phase 2 clinical trials in Sjögren-Larsson Syndrome (SLS) and noninfectious anterior uveitis, working capital, and general corporate purposes.

“Following our recent successful capital raise of $7.79 million through a private placement which closed on January 14, 2015, we are pleased to obtain this commitment for additional financing to continue to execute on our business strategy,” commented Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. “This investment is expected to enable us to further expand the development of our aldehyde trap platform to include new indications.”

Pursuant to the terms of the Purchase Agreement, Aldeyra has agreed to sell an aggregate of 211,528 shares of common stock at a price of $9.33 per share, which represents the closing consolidated bid price per share of common stock on the trading day immediately preceding the execution of the Purchase Agreement, and a warrant to purchase up to 211,528 shares of common stock at a price of $0.125 per share subject to the warrant. The exercise price of the warrant is $9.50 per share. The warrant will expire 3 years from the date on which the warrant is issued. The warrant does not include a net-exercise feature. The warrant may be redeemed by Aldeyra at a price of $0.001 per share upon notice to the holders thereof in the event that the closing bid for Aldeyra’s common stock for each of the fifteen consecutive trading days prior to such redemption is at least $20.00 per share and the average trading volume of Aldeyra’s common stock during such period is 50,000 shares per day. Following Aldeyra’s notification to the investor of its exercise of the redemption right under the warrant, the investor will have the option to exercise the warrant prior to the redemption date rather than having them redeemed.

The closing of the offering is subject to the satisfaction of customary closing conditions.

The securities sold as part of the Purchase Agreement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. Aldeyra has agreed to file a registration statement with the SEC registering the resale of the shares of common stock and the shares underlying the warrant.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to initiate Phase II clinical studies of NS2 in Sjögren-Larsson Syndrome and noninfectious anterior uveitis in early 2015. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding, among other things, the expected closing and closing date of the financing and the use of proceeds of the financing. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “aim,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra’s forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyra’s product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra’s product candidates; the size and growth of the potential markets for Aldeyra’s product candidates and the ability to serve those markets; Aldeyra’s expectations regarding Aldeyra’s expenses and revenue, the sufficiency of Aldeyra’s cash resources and needs for additional financing; Aldeyra’s ability to attract or retain key personnel; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 which is on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.

In addition to the risks described above and in Aldeyra’s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra’s results.  No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

CONTACT: Corporate Contact:
         Stephen Tulipano
         Aldeyra Therapeutics, Inc.
         Tel: +1 781-761-4904 Ext. 205
         stulipano@aldeyra.com

         Investor Contact: 
         David Burke
         The Ruth Group
         Tel: +1 646-536-7009
         dburke@theruthgroup.com

(BTG) Update: Higher Grade Gold at Wolfshag Zone, Otjikoto Mine, Namibia

B2Gold Corp.
Ian MacLean
Vice President, Investor Relations
604-681-8371

B2Gold Corp.
Shaun Johnson
Investor Relations Associate
604-681-8371
www.b2gold.com

(MEIL) to Receive $4 Million for a Limited License of Its Technology

LAS VEGAS, NV – January 20, 2015 / Methes Energies International Ltd. (NASDAQ:MEIL), announced today that it has granted a U.S. based entity (the “Licensee”) a non-exclusive license to use Methes’ design and software for a 3,000 liter per hour biodiesel processor to manufacture biodiesel processors for its own projects in the United States. Methes is to receive a $4 million upfront cash payment and will be entitled to an additional $100,000 for each of the first 40 units manufactured by the Licensee. Payment of the initial $4 million license fee is scheduled to be received on or before February 20, 2015 which provides sufficient time for Methes to gather and package design information to be delivered to Licensee.

Under a separate Consulting Agreement, Methes will collaborate with the Licensee on the manufacture of the first five units. This transaction does not include any other Methes technologies including Methes’ new pre-treatment process using the PP-MEC catalyst. Other products and services to be provided by Methes will be covered by separate agreements.

Nicholas Ng, President of Methes said, “What a great way to start 2015! We have been working on this project for a long time and we are very excited with the significant up-front payment and validation of our technology and what this new relationship means for our future. The Licensee is well funded and well organized to lead such a large project over the next several years. They have already identified over a dozen strategic locations across the US where they intent to install biodiesel processors. Again, it took a while but they have done this right and with the right partners in the oil & gas industry. Just like us, they see a bright future for the biodiesel industry. We are very proud that they have selected us and recognize the experience and the great technology we bring to the table.”

This week Methes is attending the 2015 National Biodiesel Conference & Expo in Ft. Worth, Texas. From January 19 to January 22 you can visit the Methes team at booth # 423.

About Methes Energies International Ltd.

Methes Energies International Ltd. is a renewable energy company that offers a variety of products and services to biodiesel fuel producers. Methes also offers biodiesel processors that are unique, truly compact, fully automated state-of-the-art and continuous flow that can run on a wide variety of feedstocks. Methes markets and sells biodiesel fuel produced at its showcase production facility in Mississauga, Ontario, Canada, and at its 13 MGY facility in Sombra, Ontario, to customers in the U.S. and Canada, as well as providing multiple biodiesel fuel solutions to its clientele. Among its services are selling commodities to its network of biodiesel producers, selling their biodiesel production and providing clients with proprietary software to operate and control their processors. Methes also remotely monitors the quality and characteristics of its clients’ production, upgrades and repairs their processors and advises clients on adjusting their processes to use varying feedstock to improve the quality of their biodiesel. For more information, please visit www.methes.com.

Forward-looking Statements

This press release contains forward-looking statements regarding future events and financial performance. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “except,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of these terms and other comparable terminology. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. There are or may be important factors that could cause our actual results to materially differ from our historical results or from any future results expressed or implied by such forward looking statements. These factors include, but are not limited to, those discussed under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended November 30, 2013, filed on February 25, 2014, as amended, which is available at the U.S. Securities and Exchange Commission website at www.sec.gov. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact
Methes Energies International Ltd.
Michel G. Laporte, Chairman and CEO
702-932-9964

(VBLT) Announces Ron Cohen and Philip Serlin Nominated to Board of Directors

TEL AVIV, Israel, Jan. 20, 2015  — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory disease, today announced the nomination of industry veterans Ron Cohen, M.D., and Philip Serlin, C.P.A. to stand for election to the Board of Directors at VBL’s extraordinary general meeting of shareholders, scheduled for February 11, 2015. Both individuals currently are leaders of biotechnology companies publicly traded in the US: Dr. Cohen serves as the President and Chief Executive Officer of Acorda Therapeutics, Inc. (Nasdaq:ACOR) and Mr. Serlin is Chief Financial and Operating Officer of BioLineRx Ltd. (Nasdaq:BLRX).

“I am pleased to welcome both Ron and Phil to the proposed slate of directors, which represents a vote of confidence in VBL and our strong and innovative therapeutic pipeline,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “The depth of industry experience represented by these nominees will be invaluable as we continue to advance our clinical development pipeline. Their wide range of expertise, which includes research and development, commercial operations and financial accounting for publicly traded U.S. and Israeli companies, will be critical to VBL and we look forward to their contributions to the Company’s continued success.”

Bennett Shapiro, M.D., Chairman of the Board of Directors at VBL, said, “We are enthusiastic about working with Ron and Phil to develop VBL further during this important year as we expect key data in both our cancer and inflammation programs.”

In addition to his position at Acorda, Dr. Cohen is a member of the Executive Committee and Vice Chair of the Health Section of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of Dyax Corp (Nasdaq:DYAX). He previously served as the Director and Chairman of the New York Biotechnology Association, and also serves as a member of the Columbia-Presbyterian Health Sciences Advisory Council. Dr. Cohen received his M.D. from Columbia University’s College of Physician & Surgeons, and his B.A. in psychology, with honors, from Princeton. He completed his residency in Internal Medicine at the University of Virginia Medical Center and is Board Certified in Internal Medicine.

Prior to joining BioLineRx in 2009, Mr. Serlin was the Chief Financial Officer and Chief Operating Officer of Kayote Networks Ltd., and before that, he served as the Chief Financial Officer of Tescom Software Systems Testing Ltd. Mr. Serlin has also held senior positions at Chiaro Networks Ltd. and at Deloitte, where he headed the SEC and U.S. Accounting Department at the National Office in Tel Aviv, as well as at the SEC headquarters in Washington, D.C. He currently serves as a Director of Kitov Pharmaceuticals (TASE:KTOV). Mr. Serlin is a C.P.A. and holds a master’s degree in Economics and Public Policy from The George Washington University and a B.Sc. in accounting from Yeshiva University.

About VBL:

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. VBL Therapeutics’ clinical pipeline is based on two distinct, proprietary platform technologies—an oncology program and an anti-inflammatory program—that leverage the body’s natural physiologic and genetic regulatory elements. The Company’s lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the pivotal Phase 3 trial for VB-111 in rGBM in the first half of 2015, under a special protocol assessment agreement granted by the FDA. VBL Therapeutics’ lead product candidate from its anti-inflammatory program, VB-201, is an oral small molecule currently being evaluated in Phase 2 clinical trials for psoriasis and for ulcerative colitis, with top-line results expected in the first quarter of 2015.

Forward Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Hannah Deresiewicz
         Stern Investor Relations, Inc.
         212-362-1200, hannahd@sternir.com

(SQBG) New Retail Partnership With HSN for The Franklin Mint(R) Brand

NEW YORK, Jan. 20, 2015  — Sequential Brands Group, Inc. (Nasdaq:SQBG) announced today that it has entered into a long-term partnership with leading entertainment and lifestyle retailer HSN to present a selection of the best branded collectible and memorabilia products that The Franklin Mint® will be offering to consumers.

“We look forward to working with The Franklin Mint and reintroducing this iconic American retail brand to our customers,” said Anne Martin-Vachon, Chief Merchandising Officer for HSN. “Through this new partnership, HSN will be able to offer our customers an impressive array of collectibles that commemorate important moments in history and strengthen the bonds between family and friends.”

The Franklin Mint, which is celebrating its 50^th anniversary will debut on HSN on Friday, January 23, at 12 p.m (EDT) / 9 a.m. (PST), and feature such iconic products as the Jackie O pearl necklace and earrings collection; replicas of the original Louis Comfort Tiffany Lamps currently on display at the Metropolitan Museum of Art; limited edition military timepieces; and an exclusive Pope John Paul II collectible, among others – all exclusive to HSN.

The Franklin Mint has also enlisted popular appraiser and historian Elyse Luray, one of the hosts of History Detectives on PBS and host of SyFy series Collection Intervention, to serve as an on-air guest during the HSN launch. All items will be available for purchase on HSN.com, beginning January 23^rd.

“Our partnership with HSN is an important step in a multi-year strategic plan to reintroduce The Franklin Mint brand to a global audience,” said Rick Platt, Group President, Brand Management of Sequential Brands Group, which owns The Franklin Mint. “Over the past year, we have begun to strengthen the distribution channels for this historic brand by securing multi-channel retail relationships, re-launching its website in partnership with Delivery Agent, and adding exciting new product categories.”

The Franklin Mint is known as the “gold standard” in the collectible and gift-giving arena with its mission of delivering “quality, integrity and creativity.” Over its long and celebrated history, The Franklin Mint brand has touched millions of consumers and collectors with a breadth of products ranging from coins and figurines to die cast vehicles and games, with sales levels that approached $1 billion a year at its peak.

About Sequential Brands Group, Inc.

Sequential Brands Group, Inc. (Nasdaq:SQBG) owns, promotes, markets, and licenses a portfolio of consumer brands that presently includes Ellen Tracy®, William Rast®, And1®, Avia®, People’s Liberation®, DVS®, Heelys®, Caribbean Joe®, Revo®, Nevados®, Linens-N-Things® and The Franklin Mint®. Sequential seeks to ensure that its brands continue to thrive and grow by employing strong brand management, design and marketing teams. Sequential has licensed and intends to license its brands in a variety of consumer categories to retailers, wholesalers and distributors in the United States and in certain international territories. For more information, please visit Sequential’s corporate website at: www.sequentialbrandsgroup.com. To inquire about licensing opportunities, please email: newbusiness@sbg-ny.com.

About HSN

HSN is a leading interactive entertainment and lifestyle retailer, offering a curated assortment of exclusive products and top brand names to its customers. HSN incorporates entertainment, inspiration, personalities and industry experts to provide an entirely unique shopping experience. At HSN, customers find exceptional selections in Health & Beauty, Jewelry, Home/Lifestyle, Fashion/Accessories, and Electronics. HSN broadcasts live to 95 million households in the US in HD 24/7 and its website – HSN.com features more than 50,000 product videos. Mobile applications include HSN apps for iPad, iPhone and Android. HSN, founded 37 years ago as the first shopping network, is an operating segment of HSN, Inc. (Nasdaq:HSNI). For more information, please visit HSN.com, or follow @HSN on Facebook and Twitter.

CONTACT: Media Contacts:
         Lewis Goldberg / Caitlin Kasunich
         lgoldberg@sbg-ny.com / ckasunich@sbg-ny.com
         212-896-1216 / 212-896-1241

(SWHC) Updates Financial Expectations

– Increasing Guidance for Third Quarter and Full 2015 Fiscal Year Net Sales and Earnings Per Share – Financial Results Conference Call Scheduled for March 3, 2015

SPRINGFIELD, Mass., Jan. 20, 2015  —Smith & Wesson Holding Corporation (NASDAQ Global Select: SWHC), a leader in firearm manufacturing and design, today announced updated expectations regarding financial results for the company’s third quarter, which will end January 31, 2015, and for its full 2015 fiscal year, which will end April 30, 2015.

The company is increasing its guidance for its third quarter and full fiscal 2015. The company indicated that it has seen recent, positive trends in the primary indicators it uses to assess its business and the consumer firearm market.  In addition, on December 11, 2014, the company successfully completed the acquisition of Battenfeld Technologies, Inc. (BTI), and this revised guidance includes estimated BTI results.

Financial Outlook

For the third quarter of fiscal 2015, the company expects net sales of between $124.0 million and $126.0 million and GAAP earnings per diluted share from continuing operations of between $0.10 and $0.11. Those GAAP earnings include expected one-time BTI acquisition costs of $0.02 per diluted share related to amortization of backlog and $0.03 per diluted share related to deal costs. Without those one-time acquisition costs, third quarter earnings per diluted share for the company from continuing operations would be expected to be between $0.15 and $0.16.

For full 2015 fiscal year, the company expects net sales of between $526.0 million and $530.0 million and GAAP earnings per diluted share from continuing operations of between $0.68 and $0.72. Those GAAP earnings include expected one-time BTI acquisition costs of $0.03 per diluted share related to amortization of backlog and $0.03 per diluted share related to deal costs. Without those one-time acquisition costs, full year earnings per diluted share for the company from continuing operations would be expected to be between $0.74 and $0.78.

Conference Call and Webcast

The company will host a conference call and webcast on March 3, 2015, to discuss its third quarter fiscal 2015 financial and operational results. Speakers on the conference call will include James Debney, President and Chief Executive Officer, and Jeffrey D. Buchanan, Executive Vice President and Chief Financial Officer. The conference call may include forward-looking statements. The conference call and webcast will begin at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Those interested in listening to the conference call via telephone may call directly at 866-825-3209 and reference conference code 40677276.  No RSVP is necessary.  The conference call audio webcast can also be accessed live and for replay on the company’s website at www.smith-wesson.com, under the Investor Relations section. The company will maintain an audio replay of this conference call on its website for a period of time after the call. No other audio replay will be available.

About Smith & Wesson

Smith & Wesson Holding Corporation (NASDAQ Global Select: SWHC) is a U.S.-based leader in firearm manufacturing and design, delivering a broad portfolio of quality firearms, related products, and training to the global military, law enforcement, and consumer markets. The company’s brands include Smith & Wesson®, M&P®, and Thompson/Center Arms™. Smith & Wesson facilities are located in Massachusetts, Maine, Connecticut, and Missouri. For more information on Smith & Wesson, call (800) 331-0852 or log on to www.smith-wesson.com.

Safe Harbor Statement                    

Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and we intend that such forward-looking statements be subject to the safe-harbor created thereby.  Such forward-looking statements include statements regarding our having seen recent, positive trends in the primary indicators we use to assess our business and the consumer firearm market; and our expectations for net sales, GAAP earnings per diluted share from continuing operations, one-time BTI acquisition costs, and earnings per diluted share from continuing operations excluding one-time BTI acquisition costs for the third quarter of fiscal 2015 and for fiscal 2015.  We caution that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by such forward-looking statements.  Such factors include the demand for our products; the state of the U.S. economy in general and the firearm industry in particular; our ability to integrate the assets we acquired from our principal injection molding supplier in a successful manner; the success of our partnership with General Dynamics Ordnance and Tactical Systems; the general growth of our firearm accessories business; difficulties in the integration of BTI with our company; the potential loss of key personnel, customers, or suppliers following the acquisition of BTI; the potential for cancellation of orders from our backlog; and other risks detailed from time to time in our reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2014.

Contact: Liz Sharp, VP Investor Relations
Smith & Wesson Holding Corp.
(413) 747-3304
lsharp@smith-wesson.com

Elephant Talk Communications Inc. (ETAK)

Elephant Talk Communications Inc. provides mobile proprietary Software Defined Network Architecture (ET Software DNA® 2.0) platforms for its growing base of strategic partners and clients, which includes some of today’s world-leading MNOs and technology companies, including Vodafone, T-Mobile, Zain, HP and Affirmed Networks.

Targeting its share of the broader $1.4+ trillion telecommunications market, Elephant Talk empowers MNOs, MVNOs, MVNEs and MVNAs with a full suite of applications, reliable industry expertise, and high quality customer service. Understanding that partnership is crucial in enabling and delivering the highest level of quality of product capability and professionalism, Elephant Talk also closely collaborates with other expert organizations and leading service providers.

ValidSoft UK Ltd., a subsidiary of Elephant Talk uses personal authentication and device assurance to secure transactions and help customers reduce fraud losses. As part of its multi-factor authentication, ValidSoft integrates its leading Voice Biometric engine into multivendor solutions or as a standalone system. ValidSoft serves multiple clients in the financial government and business automation sectors and is the only company to have been granted four European Privacy Seals, reflecting its commitment to promoting strong data privacy.

Elephant Talk has implemented rigid structures and processes to ensure corporate integrity and the responsible oversight of all business activities. This vision starts with executive management and extends to every employee. Elephant Talk is guided by a visionary leadership team with a rich history of success in key markets pertinent to both the company’s current and desired market positions. In order to achieve and maintain world-class system performance, Elephant Talk leverages this management team along with collaborations with the world’s best technical partners.

(MCHX) Announces Regular Quarterly Dividend for Common Stock

Marchex, Inc. (NASDAQ:MCHX), today announced that the company’s Board of Directors has declared a regular quarterly dividend in the amount of $0.02 per share on its common stock. Marchex will pay these dividends on February 17, 2015, to the holders of record as of the close of business on February 6, 2015.

Marchex commenced the payment of a regular quarterly cash dividend on its common stock on February 15, 2007. The company intends to pay a regular quarterly dividend on its common stock for the foreseeable future at the discretion of the Board of Directors depending on available cash, anticipated cash needs, overall financial condition, future prospects for earnings and cash flows as well as other relevant factors.

About Marchex

Marchex is a mobile advertising technology company. The company provides a suite of products and services for businesses that depend on consumer phone calls to drive sales. Marchex’s mobile advertising platform delivers new customer phone calls to businesses, while its technology analyzes the data in these calls to help maximize ad campaign results. Marchex disrupts traditional advertising models by giving businesses full transparency into their ad campaign performance and charging them based on new customer acquisition.

Please visit www.marchex.com, blog.marchex.com or @marchex on Twitter (Twitter.com/Marchex), where Marchex discloses material information from time to time about the company, its financial information, and its business.

Forward-Looking Statements:

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, acquisitions, projected costs, prospects, plans and objectives of management are forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. There are a number of important factors that could cause Marchex’s actual results to differ materially from those indicated by such forward-looking statements which are described in the “Risk Factors” section of our most recent periodic report and registration statement filed with the SEC. All of the information provided in this release is as of January 16, 2015, and Marchex undertakes no duty to update the information provided herein.

Marchex Investor Relations
Trevor Caldwell, 206-331-3600
Email: ir(at)marchex.com
or
MEDIA INQUIRIES
Marchex Corporate Communications
Sonia Krishnan, 206-331-3434
Email: skrishnan(at)marchex.com

(ORMP) Granted Patent in Israel for Oral Administration of GLP-1

JERUSALEM, January 16, 2015  —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Israel Patent Office has granted the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Exenatide.”

About ORMD-0901 – Oral GLP-1

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and is indicated for treatment of type 2 diabetes. Exenatide induces insulin release at increased glucose levels and causes a feeling of satiety, which results in reduced food intake and weight loss. Oramed’s oral GLP-1 capsule based on the company’s POD^TM technology could significantly increase compliance and become a valuable tool in the treatment of diabetes.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD^TM) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition the company is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com

Forward-looking statements:  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss the impact that our oral GLP-1 could have on compliance, whether our oral GLP-1 will become a valuable tool in the treatment of diabetes, our clinical trials, including the expected timing thereof, and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Company Contact
Oramed Pharmaceuticals
Ariella Vaystooch
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: ariella@oramed.com

(ATVI) Delivers Top Global Games of 2014

Skylanders Trap Team Outsells Nearest Competitor Globally by 17%; Skylanders Franchise 30% Bigger than Nearest Competitor Globally Call of Duty: Advanced Warfare Top-selling Console Game of 2014 Globally; #1 Gaming Franchise in US for Sixth Straight Year Destiny is #2 Top-Selling Video Game in the US Based on Revenue; Biggest New Video Game Franchise Launch in History

Activision Publishing, Inc., a wholly owned subsidiary of Activision Blizzard, Inc. (NASDAQ: ATVI), delivered the top-selling console video game of 2014 with Call of Duty®: Advanced Warfare and the top-selling kids video game in the world with Skylanders Trap Team.¹ Call of Duty: Advanced Warfare topped the U.S. charts for 2014 and claimed the title of the #1 top-selling console game of 2014 globally.¹ Call of Duty is also the #1 franchise in the U.S. for the sixth year in a row in the U.S., based on revenue.² Skylanders® Trap Team is the #1 top-selling kids video game globally, and Skylanders is the #1 kids video game franchise of the year in the U.S, and globally, for the third year in a row, based on retail sell-through including toys and accessories.¹

“We’d like to thank our fans for making Call of Duty: Advanced Warfare the #1 top-selling video game in the world, Skylanders Trap Team the top-selling kids game in the world and Destiny the #1 new video game IP of 2014,” said Eric Hirshberg, CEO of Activision Publishing. “As much fun as we had making these games, we’ve had even more fun playing alongside you. Stay tuned. We have more exciting games in store for fans this year.”

In addition to these wins, Destiny, the epic new game from Activision and Bungie, is the #2 top-selling console game among all titles in the U.S. in 2014, based on revenue.² Destiny is also the top-selling new video game IP of the year and had the biggest launch of a new video game franchise in history.¹ And Skylanders continued to lead the ‘Toys to Life’ category for the third consecutive year.

“Skylanders continues its leadership position as the #1 kids video game franchise globally as well as in the U.S. by wide margins. As a global franchise in 2014, Skylanders is 30% bigger than its nearest competitor. And Skylanders Trap Team outsold its nearest competitor globally by 17%,” said Eric Hirshberg, CEO of Activision Publishing. “As the creators of the ‘Toys to Life’ category, we are thrilled to continue to lead it for the third consecutive year.”

Call of Duty: Advanced Warfare is developed by Sledgehammer Games for Xbox One, the all-in-one games and entertainment system from Microsoft, PlayStation®4 computer entertainment system and PC, and is available via direct digital download. A current gen version for Xbox 360 games and entertainment system from Microsoft and PlayStation®3 computer entertainment system is also available. The title is rated M for Mature with Blood and Gore, Drug Reference, Intense Violence and Strong Language.

For the latest intel, check out: www.callofduty.com, www.facebook.com/callofduty, www.youtube.com/callofduty or follow @CallofDuty on Twitter and Instagram.

Skylanders® Trap Team introduces a ground-breaking innovation that lets Portal Masters “trap” the most wanted villains in Skylands and then play as them in the game in the battle for good. The game offers an unprecedented new addition to the game’s play pattern in the form of Traptanium™ Traps. When this new type of toy is placed into the Traptanium Portal^TM, Portal Masters can “capture” a variety of special villains from the game and magically transport them from Skylands into the real world — effectively bringing life to toys. Additionally, Skylanders Trap Team advances the gaming industry by offering the full AAA game experience on both tablet and console for the first time ever.

The fourth installment of the award-winning, $2 billion game franchise, Skylanders Trap Team is playable with more than 175 unique toys from all previous Skylanders games. Every character is able to defeat and trap villains using Traptanium™ Traps, providing fans more ways to enjoy their collections. The game is available on the following platforms: Nintendo’s Wii™ system and Nintendo’s Wii U™ system; a variety of iPads®, Kindle Fire and Android tablets; Xbox One and Xbox 360 games and entertainment systems from Microsoft; PlayStation® 3 and PlayStation® 4 computer entertainment systems from Sony. A different adventure is also available on the Nintendo 3DS™ hand-held system. For more information, please visit: www.skylanders.com and Activision.com/presscenter.

Destiny casts players as a Guardian of the last city on Earth, able to explore the ancient ruins of our solar system in a social, living universe filled with other players. Players will journey through environments spanning the red dunes of Mars to the lush jungles of Venus while creating their own legend as they and their friends venture out into the stars to reclaim the treasures and secrets lost after the collapse of humanity. Over the course of their adventures, players will become more powerful as they wield rare and exotic weapons, gear, and super abilities.

Destiny is rated T for Teen by the ESRB (Animated Blood and Violence), and is available now for the PlayStation®4 computer entertainment system (PlayStation Plus required for some features), PlayStation®3 computer entertainment system, Xbox One, the all-in-one games and entertainment system and Xbox 360 games and entertainment system from Microsoft (Xbox Live Gold required for some features).

For more information, visit www.DestinyTheGame.com. For exclusive updates, follow the official Destiny social channels at www.facebook.com/DestinyTheGame and @DestinyTheGame on Twitter, and interact directly with the developers at www.Bungie.net.

About Activision Publishing, Inc.

Headquartered in Santa Monica, California, Activision Publishing, Inc. is a leading global producer and publisher of interactive entertainment. Activision maintains operations throughout the world. More information about Activision and its products can be found on the company’s website, www.activision.com.

© 2015 ACTIVISION, CALL OF DUTY, CALL OF DUTY ADVANCED WARFARE, SKYLANDERS, SKYLANDERS TRAP TEAM, TRAPTANIUM, TRAPTANIUM PORTAL are trademarks of Activision Publishing, Inc.

© 2015 Bungie, Inc. All rights reserved. Destiny, the Destiny Logo, Bungie and the Bungie Logo are among the trademarks of Bungie, Inc. Published and distributed by Activision.

“PlayStation” and “PS3” are registered trademarks. “PS4” is a trademark of Sony Computer Entertainment Inc.

All other trademarks or trade names are the properties of their respective owners.

¹ Based on physical game unit sell-through data, according to NPD, GfK, and Activision internal estimates.
² Based on physical game unit-sell through, according to NPD.

(NYNY) Largest Stockholder Exercises Basic Subscription Rights in Rights Offering

$30.68 Million Gross Proceeds to Company

Empire Resorts, Inc. (NASDAQ-GM:NYNY) announced that Kien Huat Realty III Limited (“Kien Huat”), the Company’s largest stockholder, exercised the basic subscription rights it was granted in the Company’s ongoing rights offering on Thursday, January 15, 2015 at $7.10 per share. Such exercise generated approximately $30.68 million of gross proceeds to the Company.

In accordance with a standby purchase agreement executed by the Company and Kien Huat in relation to the rights offering, Kien Huat has further agreed it would exercise all rights not otherwise exercised by the other holders in the rights offering in an aggregate amount not to exceed $50 million. The Company will pay Kien Huat a commitment fee of $250,000 pursuant to the standby purchase agreement. In addition, the Company will reimburse Kien Huat for its expenses related to the standby purchase agreement in an amount not to exceed $40,000. The consummation of the transactions contemplated by the standby purchase agreement is subject to customary closing conditions.

The Company distributed to its common stock holders and Series B Preferred Stock holders one non-transferable right to purchase one share of common stock at a subscription price of $7.10 per share for each 5.6 shares of common stock owned, or into which their Series B Preferred Stock was convertible, on January 2, 2015, the record date for the offering. In addition to being able to purchase their pro rata portion of the shares offered based on their ownership as of January 2, 2015, stockholders may oversubscribe for additional shares of common stock. Holders of rights may exercise their subscription rights to purchase additional shares of our common stock at the subscription price per share until prior to 5:00 p.m., New York City time, on February 2, 2015, subject to extension and earlier termination. Subscription rights not exercised by such time and date will expire and have no value.

Registration Statement

The Company has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Company or our information agent, Morrow & Co., LLC, will arrange to send you the prospectus if you request it by calling (855) 201-1081.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release that are not historical facts are “forward-looking statements” that may involve material risks and uncertainties. The company wishes to caution readers not to place undue reliance on such forward-looking statements, which statements are made pursuant to the Private Securities Litigation Reform Act of 1995, and as such, speak only as of the date made. For a full discussion of risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the company’s registration statement on Form S-3 and the prospectus relating to the rights offering, dated January 5, 2015.

About Empire Resorts

Empire Resorts owns and operates, through its subsidiary Monticello Raceway Management, Inc., the Monticello Casino & Raceway, a harness racing track and casino located in Monticello, New York, and is 90 miles from midtown Manhattan. Further information is available at www.empireresorts.com and www.montreign.com.

(EOPN) Adopts One Year Stockholder Rights Plan

FOSTER CITY, Calif., Jan. 16, 2015  — E2open, Inc. (NASDAQ:EOPN) (“E2open”), the leading provider of cloud-based solutions for collaborative planning and execution across global trading networks, today announced that its Board of Directors has unanimously adopted a stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of one preferred share purchase right on each outstanding share of E2open’s common stock. The Rights Plan has a term of one year.

The Board of Directors adopted the Rights Plan in order to help promote the fair and equal treatment of all stockholders and enable them to realize the long-term value of their investment in E2open. The Rights Plan is also designed to reduce the likelihood that any person or group would gain control of E2open through open market accumulation or other coercive tactics without paying an appropriate control premium. The Rights Plan is not intended to interfere with any transaction approved by the Board of Directors. The Board of Directors is committed to acting in the best interests of all of E2open’s stockholders.

Pursuant to the Rights Plan, E2open will issue one preferred stock purchase right for each share of common stock outstanding at the close of business on January 26, 2015. Each right will entitle stockholders to buy one one-thousandth of a share of Series A participating preferred stock at an exercise price of $30.00. Initially, these rights will not be exercisable and will trade with E2open’s common stock.

In general terms, the Rights Plan imposes a significant penalty upon any person or group that acquires 10% (or 20% in the case of institutional investors who report their holdings on Schedule 13G, as described in the Rights Plan) or more of E2open’s common stock without the approval of the Board of Directors.

Under the Rights Plan, the rights generally will become exercisable only if a person or group acquires beneficial ownership of 10% (or 20% in the case of institutional investors who report their holdings on Schedule 13G) or more of E2open’s common stock (including through entry into certain derivative positions) in a transaction not approved by the Board of Directors. In that situation, each holder of a right (other than the acquiring person, whose rights will become void and will not be exercisable) will have the right to purchase, upon payment of the exercise price, a number of shares of E2open’s common stock having a then-current market value equal to twice the exercise price. In the case of a person or group that already owns in excess of 10% of E2open’s common stock (other than institutional investors who report their holdings on Schedule 13G), the rights generally will become exercisable only if that person or group acquires beneficial ownership of any additional shares of E2open’s common stock.

In addition, if E2open is acquired in a merger or other business combination after an acquiring person acquires 10% (or 20% in the case of 13G institutional investors who report their holdings on Schedule 13G) or more of E2open’s common stock, each holder of the right will thereafter have the right to purchase, upon payment of the exercise price, a number of shares of common stock of the acquiring person having a then-current market value equal to twice the exercise price. The acquiring person will not be entitled to exercise these rights.

The Board of Directors may redeem the rights for a nominal amount at any time on or prior to the 10th business day (or such later date as it determines) following an event that causes the rights to become exercisable. Under the Rights Plan’s terms, it will expire on January 16, 2016.

Additional details about the Rights Plan will be contained in a Current Report on Form 8-K to be filed by E2open with the Securities and Exchange Commission.

Wilson Sonsini Goodrich & Rosati, Professional Corporation, is acting as E2open’s legal counsel.

About E2open

E2open (NASDAQ: EOPN) is the leading provider of cloud-based, on-demand software solutions enabling enterprises to procure, manufacture, sell, and distribute products more efficiently through collaborative planning and execution across global trading networks. Enterprises use E2open solutions to gain visibility into and control over their trading networks through the real-time information, integrated business processes, and advanced analytics that E2open provides. E2open customers include Avnet, Celestica, Cisco, HP, IBM, Lenovo, L’Oreal, Motorola Solutions, Seagate, and Vodafone. E2open is headquartered in Foster City, California with operations worldwide. For more information, visit www.e2open.com.

Media Contact:
Michael Fox, ICR
203-682-8218
Michael.Fox@icrinc.com

Investor Relations Contact:
Greg Kleiner, ICR
investor.relations@e2open.com
(650) 645-6675